Marc Maliepaard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3521392/publications.pdf

Version: 2024-02-01

| | | 1478505 | 996975 |
|----------|----------------|--------------|----------------|
| 15 | 392 | 6 | 15 |
| papers | citations | h-index | g-index |
| | | | |
| | | | |
| | | | |
| 15 | 15 | 15 | 539 |
| all docs | docs citations | times ranked | citing authors |
| | | | |

| # | Article | IF | Citations |
|----|---|------|-----------|
| 1 | Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency. Frontiers in Medicine, 2022, 9, . | 2.6 | 4 |
| 2 | Impact of the new European Union <i>In Vitro</i> Diagnostics Regulation on the practice of hospital diagnostic laboratories. Expert Review of Molecular Diagnostics, 2022, 22, 583-590. | 3.1 | 4 |
| 3 | Comment on "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?― Clinical Pharmacokinetics, 2020, 59, 281-282. | 3.5 | 3 |
| 4 | Pharmacokinetics and Generic Drug Switching: A Regulator's View. Clinical Pharmacokinetics, 2020, 59, 1065-1069. | 3.5 | 6 |
| 5 | Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands. Clinical and Translational Science, 2020, 13, 599-607. | 3.1 | 3 |
| 6 | Pharmacogeneticâ€Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017. Clinical Pharmacology and Therapeutics, 2020, 108, 338-349. | 4.7 | 2 |
| 7 | Ethnicity-Specific Drug Safety Data in European Medicines Agency Registration Dossiers, European Public Assessment Reports, and European and Singapore Drug Labels: Lost in Translation?. Pharmaceutical Medicine, 2019, 33, 407-416. | 1.9 | 3 |
| 8 | The mechanisms of pharmacokinetic food-drug interactions $\hat{a} \in \text{``A perspective from the UNGAP group.}$ European Journal of Pharmaceutical Sciences, 2019, 134, 31-59. | 4.0 | 224 |
| 9 | Interchangeability of Genericsâ€"Experiences and Outlook Toward Pharmacokinetics Variability and Genericâ€Generic Substitution. Clinical Pharmacology and Therapeutics, 2019, 105, 292-294. | 4.7 | 4 |
| 10 | Interchangeability of Generic Drugs: A Nonparametric Pharmacokinetic Model of Gabapentin Generic Drugs. Clinical Pharmacology and Therapeutics, 2018, 104, 966-973. | 4.7 | 6 |
| 11 | A comparison of the intrasubject variation in drug exposure between generic and brandâ€name drugs: a retrospective analysis of replicate design trials. British Journal of Clinical Pharmacology, 2016, 81, 667-678. | 2.4 | 18 |
| 12 | Investigation into the interchangeability of generic formulations using immunosuppressants and a broad selection of medicines. European Journal of Clinical Pharmacology, 2015, 71, 979-990. | 1.9 | 18 |
| 13 | Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nature Reviews Drug Discovery, 2013, 12, 103-115. | 46.4 | 66 |
| 14 | Interchangeability of generic anti-epileptic drugs: a quantitative analysis of topiramate and gabapentin. European Journal of Clinical Pharmacology, 2011, 67, 1007-1016. | 1.9 | 24 |
| 15 | Requirements for generic anti-epileptic medicines: a regulatory perspective. Journal of Neurology, 2009, 256, 1966-1971. | 3.6 | 7 |